 Benjamin Click
Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 38 | 2025 | 216 | 13.920 |
Why?
| | Inflammatory Bowel Diseases | 31 | 2025 | 320 | 8.860 |
Why?
| | Colitis, Ulcerative | 13 | 2024 | 119 | 3.510 |
Why?
| | Ileum | 13 | 2025 | 116 | 3.230 |
Why?
| | Recurrence | 16 | 2025 | 1004 | 2.990 |
Why?
| | Colonoscopy | 10 | 2025 | 235 | 2.950 |
Why?
| | Biological Products | 9 | 2023 | 199 | 2.510 |
Why?
| | Ustekinumab | 8 | 2024 | 13 | 2.010 |
Why?
| | Gastrointestinal Agents | 6 | 2024 | 61 | 1.820 |
Why?
| | Colon | 9 | 2025 | 252 | 1.640 |
Why?
| | Ileostomy | 4 | 2025 | 20 | 1.400 |
Why?
| | Patient-Centered Care | 4 | 2024 | 497 | 1.290 |
Why?
| | Postoperative Complications | 9 | 2025 | 2462 | 1.170 |
Why?
| | Mesentery | 2 | 2024 | 47 | 1.090 |
Why?
| | Remission Induction | 7 | 2025 | 268 | 0.940 |
Why?
| | Holistic Health | 1 | 2024 | 15 | 0.910 |
Why?
| | Anastomosis, Surgical | 6 | 2025 | 149 | 0.880 |
Why?
| | Adult | 40 | 2025 | 35299 | 0.870 |
Why?
| | Retrospective Studies | 24 | 2025 | 14471 | 0.860 |
Why?
| | Health Expenditures | 3 | 2020 | 179 | 0.860 |
Why?
| | Delivery of Health Care | 2 | 2020 | 889 | 0.800 |
Why?
| | Health Care Costs | 3 | 2020 | 366 | 0.800 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2021 | 1187 | 0.790 |
Why?
| | Humans | 68 | 2025 | 128495 | 0.780 |
Why?
| | Diverticulitis | 1 | 2022 | 8 | 0.770 |
Why?
| | Hypoalbuminemia | 1 | 2021 | 30 | 0.740 |
Why?
| | Dermatologic Agents | 1 | 2021 | 65 | 0.700 |
Why?
| | Cost of Illness | 2 | 2020 | 278 | 0.690 |
Why?
| | C-Reactive Protein | 4 | 2016 | 398 | 0.660 |
Why?
| | Proctocolectomy, Restorative | 4 | 2024 | 19 | 0.650 |
Why?
| | Patient Acceptance of Health Care | 4 | 2020 | 757 | 0.650 |
Why?
| | Health Resources | 2 | 2018 | 113 | 0.610 |
Why?
| | Gastric Bypass | 1 | 2020 | 107 | 0.610 |
Why?
| | Colonic Pouches | 3 | 2024 | 14 | 0.600 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 86 | 0.600 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 84 | 0.590 |
Why?
| | Middle Aged | 28 | 2025 | 30921 | 0.580 |
Why?
| | Risk Factors | 12 | 2025 | 9737 | 0.570 |
Why?
| | Colitis | 1 | 2020 | 240 | 0.570 |
Why?
| | Bariatric Surgery | 1 | 2020 | 192 | 0.540 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2024 | 758 | 0.540 |
Why?
| | Obesity, Morbid | 1 | 2020 | 240 | 0.530 |
Why?
| | Adenoma | 1 | 2018 | 212 | 0.510 |
Why?
| | Costs and Cost Analysis | 1 | 2016 | 200 | 0.500 |
Why?
| | Colonic Neoplasms | 1 | 2018 | 243 | 0.500 |
Why?
| | Male | 37 | 2025 | 63043 | 0.490 |
Why?
| | Eosinophilia | 1 | 2017 | 205 | 0.480 |
Why?
| | Asymptomatic Diseases | 1 | 2015 | 84 | 0.470 |
Why?
| | Blood Component Removal | 1 | 2015 | 26 | 0.470 |
Why?
| | Hypertriglyceridemia | 1 | 2015 | 39 | 0.470 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 183 | 0.470 |
Why?
| | Quality Improvement | 2 | 2020 | 1097 | 0.460 |
Why?
| | Prospective Studies | 14 | 2022 | 7069 | 0.450 |
Why?
| | Anti-Inflammatory Agents | 2 | 2017 | 470 | 0.450 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 240 | 0.450 |
Why?
| | Constriction, Pathologic | 4 | 2023 | 228 | 0.450 |
Why?
| | Pancreatitis | 1 | 2015 | 128 | 0.440 |
Why?
| | Female | 36 | 2025 | 68266 | 0.440 |
Why?
| | Antibodies, Monoclonal | 2 | 2024 | 1357 | 0.420 |
Why?
| | Severity of Illness Index | 7 | 2018 | 2719 | 0.420 |
Why?
| | Quality of Life | 10 | 2022 | 2688 | 0.420 |
Why?
| | Sweet Syndrome | 2 | 2023 | 8 | 0.400 |
Why?
| | Mental Disorders | 2 | 2017 | 1007 | 0.380 |
Why?
| | Cecum | 2 | 2023 | 32 | 0.360 |
Why?
| | Hospitalization | 3 | 2020 | 2069 | 0.360 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 751 | 0.350 |
Why?
| | Registries | 8 | 2022 | 1883 | 0.340 |
Why?
| | Disease Progression | 6 | 2022 | 2604 | 0.340 |
Why?
| | Anemia | 3 | 2016 | 160 | 0.340 |
Why?
| | Dilatation | 2 | 2020 | 59 | 0.330 |
Why?
| | Endoscopy | 2 | 2023 | 271 | 0.330 |
Why?
| | Drug Monitoring | 2 | 2022 | 190 | 0.330 |
Why?
| | Pennsylvania | 6 | 2018 | 107 | 0.320 |
Why?
| | Telemedicine | 1 | 2018 | 786 | 0.320 |
Why?
| | Anus Diseases | 2 | 2020 | 7 | 0.310 |
Why?
| | Aged | 12 | 2023 | 21974 | 0.310 |
Why?
| | Treatment Outcome | 8 | 2025 | 10162 | 0.290 |
Why?
| | Young Adult | 10 | 2025 | 12349 | 0.280 |
Why?
| | Biological Therapy | 3 | 2022 | 28 | 0.280 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 569 | 0.270 |
Why?
| | Pouchitis | 2 | 2024 | 5 | 0.270 |
Why?
| | Colectomy | 2 | 2024 | 94 | 0.260 |
Why?
| | Risk | 2 | 2019 | 853 | 0.250 |
Why?
| | Biopsy | 3 | 2024 | 1079 | 0.240 |
Why?
| | Necrosis | 2 | 2023 | 229 | 0.240 |
Why?
| | Brain | 1 | 2017 | 2624 | 0.240 |
Why?
| | Spondylarthritis | 1 | 2025 | 45 | 0.220 |
Why?
| | Neoplasms | 1 | 2019 | 2463 | 0.220 |
Why?
| | Social Isolation | 1 | 2023 | 60 | 0.210 |
Why?
| | Secondary Prevention | 1 | 2024 | 219 | 0.210 |
Why?
| | Comparative Effectiveness Research | 2 | 2021 | 146 | 0.200 |
Why?
| | Reoperation | 2 | 2022 | 544 | 0.200 |
Why?
| | Intestinal Mucosa | 2 | 2024 | 581 | 0.190 |
Why?
| | Time Factors | 6 | 2025 | 6505 | 0.190 |
Why?
| | Propensity Score | 2 | 2020 | 265 | 0.190 |
Why?
| | Anus Neoplasms | 1 | 2021 | 30 | 0.180 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2021 | 33 | 0.180 |
Why?
| | Skin Neoplasms | 2 | 2019 | 820 | 0.180 |
Why?
| | Economics, Medical | 1 | 2020 | 4 | 0.170 |
Why?
| | Rheumatic Diseases | 1 | 2021 | 69 | 0.170 |
Why?
| | Radiation Injuries | 1 | 2021 | 135 | 0.170 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 209 | 0.170 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2022 | 217 | 0.160 |
Why?
| | Electronic Health Records | 2 | 2018 | 974 | 0.160 |
Why?
| | Pulmonary Embolism | 1 | 2022 | 209 | 0.160 |
Why?
| | Fibrosis | 2 | 2020 | 513 | 0.160 |
Why?
| | Infliximab | 1 | 2020 | 100 | 0.160 |
Why?
| | Intestinal Obstruction | 1 | 2020 | 49 | 0.160 |
Why?
| | Gastrectomy | 1 | 2020 | 99 | 0.160 |
Why?
| | Analgesics, Opioid | 2 | 2018 | 889 | 0.160 |
Why?
| | Adolescent | 6 | 2022 | 20304 | 0.160 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 258 | 0.160 |
Why?
| | Drug Substitution | 1 | 2019 | 51 | 0.150 |
Why?
| | Combined Modality Therapy | 1 | 2022 | 1201 | 0.150 |
Why?
| | Sigmoidoscopy | 1 | 2018 | 11 | 0.150 |
Why?
| | Deprescriptions | 1 | 2019 | 34 | 0.150 |
Why?
| | Multivariate Analysis | 3 | 2018 | 1499 | 0.150 |
Why?
| | Health Services Misuse | 1 | 2018 | 35 | 0.150 |
Why?
| | Venous Thromboembolism | 1 | 2022 | 283 | 0.150 |
Why?
| | Linear Models | 1 | 2020 | 816 | 0.140 |
Why?
| | Pyrroles | 1 | 2019 | 190 | 0.140 |
Why?
| | Lymphoma | 1 | 2019 | 195 | 0.140 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 958 | 0.140 |
Why?
| | Thyroid Neoplasms | 1 | 2021 | 309 | 0.140 |
Why?
| | Disease Management | 2 | 2020 | 584 | 0.140 |
Why?
| | Piperidines | 1 | 2019 | 191 | 0.140 |
Why?
| | Clostridium Infections | 1 | 2017 | 62 | 0.140 |
Why?
| | Skin Diseases | 1 | 2018 | 141 | 0.130 |
Why?
| | Models, Organizational | 1 | 2017 | 145 | 0.130 |
Why?
| | Dermatology | 1 | 2018 | 117 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 622 | 0.130 |
Why?
| | Unemployment | 1 | 2016 | 42 | 0.130 |
Why?
| | Follow-Up Studies | 4 | 2018 | 4874 | 0.130 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5045 | 0.130 |
Why?
| | Drug Prescriptions | 1 | 2018 | 245 | 0.130 |
Why?
| | Intestines | 1 | 2019 | 344 | 0.120 |
Why?
| | Risk Assessment | 3 | 2022 | 3232 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2020 | 3339 | 0.120 |
Why?
| | Adalimumab | 1 | 2015 | 39 | 0.120 |
Why?
| | Surveys and Questionnaires | 5 | 2025 | 5371 | 0.120 |
Why?
| | Pyrimidines | 1 | 2019 | 449 | 0.120 |
Why?
| | Weight Loss | 1 | 2020 | 727 | 0.120 |
Why?
| | Inflammation | 2 | 2024 | 2666 | 0.120 |
Why?
| | Incidence | 2 | 2018 | 2638 | 0.120 |
Why?
| | Biomarkers | 3 | 2023 | 3893 | 0.110 |
Why?
| | Cohort Studies | 3 | 2020 | 5402 | 0.110 |
Why?
| | United States | 5 | 2025 | 13840 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 856 | 0.100 |
Why?
| | Hemoglobins | 1 | 2015 | 337 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 880 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1938 | 0.100 |
Why?
| | Patient Care Team | 1 | 2017 | 598 | 0.100 |
Why?
| | Melanoma | 1 | 2019 | 724 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2020 | 1088 | 0.090 |
Why?
| | Longitudinal Studies | 4 | 2025 | 2710 | 0.090 |
Why?
| | Prognosis | 1 | 2020 | 3780 | 0.090 |
Why?
| | Comorbidity | 1 | 2016 | 1541 | 0.090 |
Why?
| | Needs Assessment | 2 | 2022 | 356 | 0.070 |
Why?
| | Logistic Models | 3 | 2018 | 1980 | 0.070 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 996 | 0.070 |
Why?
| | Hypertension | 1 | 2016 | 1236 | 0.070 |
Why?
| | Immunologic Factors | 2 | 2021 | 231 | 0.070 |
Why?
| | Iron Compounds | 2 | 2016 | 6 | 0.060 |
Why?
| | Blood Sedimentation | 2 | 2016 | 34 | 0.060 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2023 | 29 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 198 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2022 | 7057 | 0.050 |
Why?
| | Mitomycin | 1 | 2021 | 31 | 0.050 |
Why?
| | Resilience, Psychological | 1 | 2023 | 122 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2025 | 1200 | 0.050 |
Why?
| | Sutures | 1 | 2022 | 52 | 0.050 |
Why?
| | Fistula | 1 | 2022 | 35 | 0.050 |
Why?
| | Operative Time | 1 | 2022 | 121 | 0.050 |
Why?
| | Fluorouracil | 1 | 2021 | 198 | 0.040 |
Why?
| | Feces | 1 | 2023 | 442 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 206 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 279 | 0.040 |
Why?
| | Safety | 1 | 2022 | 328 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2023 | 524 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2517 | 0.040 |
Why?
| | Phenotype | 2 | 2017 | 3051 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2022 | 863 | 0.040 |
Why?
| | Patient Preference | 1 | 2020 | 185 | 0.040 |
Why?
| | Laparoscopy | 1 | 2022 | 450 | 0.030 |
Why?
| | Anticoagulants | 1 | 2022 | 634 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 637 | 0.030 |
Why?
| | Animals | 1 | 2019 | 34647 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1871 | 0.030 |
Why?
| | Qualitative Research | 1 | 2023 | 1227 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 952 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 370 | 0.030 |
Why?
| | Pain Measurement | 1 | 2018 | 488 | 0.030 |
Why?
| | Vitamin D Deficiency | 1 | 2017 | 176 | 0.030 |
Why?
| | Depression | 1 | 2023 | 1292 | 0.030 |
Why?
| | Bacillus subtilis | 2 | 1972 | 65 | 0.030 |
Why?
| | Age Factors | 1 | 2022 | 3122 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2018 | 504 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 369 | 0.030 |
Why?
| | Liver | 1 | 2022 | 1827 | 0.030 |
Why?
| | Bacteriophages | 2 | 1972 | 92 | 0.030 |
Why?
| | DNA, Viral | 2 | 1972 | 348 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1562 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2015 | 480 | 0.020 |
Why?
| | Lysogeny | 1 | 1971 | 5 | 0.020 |
Why?
| | Biomedical Research | 1 | 2016 | 633 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2553 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3387 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1705 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 1900 | 0.020 |
Why?
| | Mutation | 2 | 1972 | 3696 | 0.010 |
Why?
| | DNA Replication | 2 | 1972 | 225 | 0.010 |
Why?
| | Centrifugation, Density Gradient | 2 | 1972 | 39 | 0.010 |
Why?
| | Tritium | 2 | 1972 | 75 | 0.010 |
Why?
| | Uridine | 2 | 1972 | 29 | 0.010 |
Why?
| | Mitomycins | 1 | 1972 | 4 | 0.010 |
Why?
| | Nitrosoguanidines | 1 | 1971 | 1 | 0.010 |
Why?
| | Temperature | 2 | 1972 | 632 | 0.010 |
Why?
| | Cell-Free System | 1 | 1971 | 47 | 0.010 |
Why?
| | Cesium | 1 | 1971 | 18 | 0.010 |
Why?
| | Mutagens | 1 | 1971 | 17 | 0.010 |
Why?
| | Spectrophotometry | 1 | 1971 | 58 | 0.010 |
Why?
| | Oxides | 1 | 1971 | 40 | 0.010 |
Why?
| | Muramidase | 1 | 1971 | 77 | 0.010 |
Why?
| | Deuterium | 1 | 1971 | 86 | 0.010 |
Why?
| | Culture Media | 1 | 1971 | 164 | 0.010 |
Why?
| | Chlorides | 1 | 1971 | 137 | 0.010 |
Why?
| | Viral Proteins | 1 | 1972 | 323 | 0.010 |
Why?
| | DNA, Bacterial | 1 | 1971 | 324 | 0.010 |
Why?
| | Bacteriolysis | 1 | 1972 | 10 | 0.000 |
Why?
| | Transferases | 1 | 1972 | 33 | 0.000 |
Why?
| | Adenine | 1 | 1972 | 256 | 0.000 |
Why?
| | Virus Replication | 1 | 1972 | 444 | 0.000 |
Why?
|
|
Click's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|